QuantX Biosciences
QuantX Biosciences is a Princeton-based, clinical-stage biotechnology company founded in 2022 that uses a proprietary computational drug discovery platform to design oral small-molecule therapeutics for immunology, inflammation, and oncology indications, with future revenue intended from pharmaceutical licensing and co-development partnerships.
- Company typePrivate
- Founded2022
- HeadquartersPrinceton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What QuantX Biosciences does
QuantX Biosciences is a privately held, clinical-stage biopharmaceutical company founded in 2022 and headquartered at 103 Carnegie Center, Suite 309, Princeton, New Jersey. The company operates a proprietary computational drug discovery platform that integrates physics-based modeling (accelerated molecular dynamics, free energy perturbation, quantum mechanics) with statistical methods, deep learning, and cheminformatics to design and optimize oral small-molecule drug candidates against clinically validated targets. Its pipeline comprises five disclosed programs: STAT6, IL-17 AA+AF, and TNFα oral small-molecule inhibitors for immunology and inflammatory diseases (atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, hidradenitis suppurativa), and PARG and Pol θ-Helicase inhibitors for solid tumors. Several programs are described as best-in-class or first-in-class oral small molecules with biologic-like efficacy and superior preclinical potency versus competitor small molecules.
The company is pre-commercial and generates no product revenue. Its business model is structured around future licensing deals, co-development arrangements, and potential acquisitions of pipeline assets by larger pharmaceutical partners, with the stated go-to-market motion being enterprise partnering rather than internal commercialization. As of February 2026, QuantX had raised $130 million in total funding, including an oversubscribed $85 million Series B co-led by LAV (Lilly Asia Ventures) and Sanofi Ventures, with participation from Hongshan and existing investors OrbiMed and Creacion Ventures. The company is led by Interim CEO Wei Li, Ph.D. (Founding Partner of Creacion Ventures), Co-founder and President Wayne Tang, Ph.D. (ex-Schrodinger, Merck), Co-founder and CTO Yax Sun, Ph.D. (ex-Amgen, Bristol-Myers Squibb), and CMO Gregory Bell, M.D. (ex-Attralus, KAI Pharmaceuticals, Genentech, Merck), with board representation from OrbiMed, Creacion Ventures, LAV, and Sanofi Ventures.
QuantX Biosciences firmographics
Firmographics- Name
- QuantX Biosciences
- Legal name
- QuantX Biosciences, Inc.
- Website
- https://quantxbio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- QuantX Biosciences is a Princeton-based, clinical-stage biotechnology company founded in 2022 that uses a proprietary computational drug discovery platform to design oral small-molecule therapeutics for immunology, inflammation, and oncology indications, with future revenue intended from pharmaceutical licensing and co-development partnerships.
- Ownership category
- akta.pro rank
QuantX Biosciences industry classification
Industry- Product category
- Computational Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where QuantX Biosciences is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
QuantX Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pipeline Development and Licensing: Pre-revenue pharmaceutical company focused on developing a pipeline of oral small molecule drug candidates. Revenue will be generated through licensing deals, co-development partnerships with larger pharmaceutical companies, and/or acquisition of pipeline assets. The company is advancing STAT6, IL-17, and TNFα inhibitors toward clinical development.
- Discovery Services / Co-development: Potential revenue from co-development arrangements and strategic partnerships with pharma companies for oral small molecule programs in immunology and inflammation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
QuantX Biosciences product offering
Product offeringCore offering
QuantX Biosciences operates a proprietary computational drug discovery platform that integrates accelerated molecular dynamics, deep learning–based molecular design, and high-precision free energy perturbation (FEP) and quantum mechanics (QM) simulations to design and optimize oral small molecule drug candidates. The company's pipeline consists of oral small molecule inhibitors targeting clinically validated immunology and inflammation targets (STAT6, IL-17 AA+AF, TNFα) plus oncology targets (PARG, Pol θ-Helicase), developed for in-licensing, co-development, or acquisition by larger pharmaceutical partners.
Product overview
QuantX Biosciences operates a computationally-driven drug discovery platform that integrates physics-based modeling, statistical methods, and computational chemistry to design and optimize oral small molecule therapeutics. The company's pipeline consists of multiple oral small molecule inhibitor programs targeting clinically validated immunology and inflammation targets: STAT6 inhibitors (for asthma, atopic dermatitis), IL-17 AA+AF inhibitors (for psoriasis, hidradenitis suppurativa), TNFα inhibitors (for rheumatoid arthritis), plus PARG and Pol θ-Helicase inhibitors for oncology. The computational platform powers iterative drug discovery from target validation through lead optimization.
Differentiator
Problem solved
Functional benefit
Products and services
- STAT6 Oral Small Molecule Inhibitor A highly potent, selective oral small molecule inhibitor targeting STAT6, a key transcription factor driving Type 2 inflammation. Being developed for atopic dermatitis, asthma, and other Type 2 inflammatory diseases, combining biologic-like efficacy with oral small molecule convenience. Intended for in-licensing or co-development by pharmaceutical partners.
- IL-17 AA + AF Oral Small Molecule Inhibitor A dual oral small molecule inhibitor targeting IL-17AA and IL-17AF for the treatment of psoriasis and broader autoimmune applications. In vivo lead compounds show superior potency versus competitor small molecules and demonstrate significant suppression of arthritis in rat CIA models. Intended for in-licensing or co-development by pharmaceutical partners.
- TNFα Oral Small Molecule Inhibitor An oral small molecule TNFα inhibitor in development for rheumatoid arthritis and broader autoimmune applications. Demonstrates best-in-class small molecule profile with good tolerability in preclinical studies, offering advantages over biologics including ease of administration and reduced immunogenicity. Intended for in-licensing or co-development by pharmaceutical partners.
- PARG Inhibitor A small molecule inhibitor targeting PARG (poly ADP-ribose glycohydrolase) being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.
- Pol θ-Helicase Inhibitor A small molecule inhibitor targeting Pol θ (DNA polymerase theta) helicase domain being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.
Quantifiable outcome
- STAT6 lead candidate is a highly potent small molecule that selectively blocks STAT6 activation, combining biologic-like efficacy with oral small molecule therapy convenience.
- +3 more outcomes
Companies that use QuantX Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
QuantX Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
QuantX Biosciences partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
QuantX Biosciences competitors and assessment
Company assessmentDirect peers
- Exscientia: Exscientia pioneered AI-designed small molecule drug discovery with multiple pharma partnerships and clinical-stage assets, including immunology indications. Comparable as a computational-first discovery company pursuing licensing and partnered development.
- InSilico Medicine: InSilico Medicine operates an AI-driven drug discovery platform (PandaOmics, Chemistry42) and has advanced multiple small molecule programs into clinical development, including immunology and oncology — comparable to QuantX's pipeline mix and platform-driven approach.
- Schrödinger: Schrödinger operates a physics-based computational drug discovery platform (FEP+, molecular dynamics) and runs internal and partnered programs — QuantX co-founder Wayne Tang previously led drug discovery at Schrödinger, making the business model, technology stack, and target classes highly comparable.
- Insitro: Insitro uses ML combined with high-throughput biology to discover and develop small molecule therapeutics. Similar positioning as a privately-held, well-funded platform biotech pursuing partnered and internal programs.
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for small molecule discovery across multiple therapeutic areas, including immunology and oncology. Comparable in applying computational methods to industrialize pipeline generation and target prioritization.
- XtalPi: XtalPi combines physics-based modeling, quantum mechanics, and AI for small molecule and crystal form prediction, with active pharmaceutical partnerships. Comparable in technology stack (FEP, QM, generative chemistry) and in serving both internal and partnered programs.
- Isomorphic Labs: Isomorphic Labs (Alphabet) applies deep learning and physics-based modeling to drug discovery with a focus on small molecules against validated targets. Comparable in applying state-of-the-art computational methods to industrialize drug design.
Emerging players
- Atomwise: Atomwise uses AI for small molecule hit identification and lead optimization across multiple therapeutic areas, with partnered programs in immunology and oncology. Comparable as an early-stage AI-discovery platform, though smaller in pipeline depth.
- BenevolentAI: BenevolentAI applies AI to drug discovery across inflammation, immunology, and rare diseases. Comparable in using computational methods to identify novel targets and indications, though focused more on target identification than on advanced lead optimization.
- Verge Genomics: Verge Genomics uses AI/ML on human multi-omics data for drug discovery, primarily in neuroscience and rare diseases. Comparable as a platform biotech using computational methods to de-risk target selection and pipeline generation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
QuantX Biosciences social profiles
Digital presenceQuantX Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuantX Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
QuantX Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuantX Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuantX Biosciences
What does QuantX Biosciences do?
QuantX Biosciences operates a proprietary computational drug discovery platform that integrates accelerated molecular dynamics, deep learning–based molecular design, and high-precision free energy perturbation (FEP) and quantum mechanics (QM) simulations to design and optimize oral small molecule drug candidates. The company's pipeline consists of oral small molecule inhibitors targeting clinically validated immunology and inflammation targets (STAT6, IL-17 AA+AF, TNFα) plus oncology targets (PARG, Pol θ-Helicase), developed for in-licensing, co-development, or acquisition by larger pharmaceutical partners.
Is QuantX Biosciences a public or private company?
QuantX Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was QuantX Biosciences founded?
QuantX Biosciences was founded in 2022. It employs 11 to 50 people.
Where is QuantX Biosciences based?
QuantX Biosciences is headquartered in Princeton, United States, in the North America region.
How does QuantX Biosciences make money?
Two revenue lines are on record. Pipeline Development and Licensing is the primary driver. The others are discovery Services / Co-development.
Who are QuantX Biosciences's main competitors?
Direct peers on record are Exscientia, InSilico Medicine, Schrödinger, Insitro, Recursion Pharmaceuticals, XtalPi and Isomorphic Labs. Emerging players are Atomwise, BenevolentAI and Verge Genomics.
Does QuantX Biosciences have an API?
No public API is recorded for QuantX Biosciences.
What industry is QuantX Biosciences in?
QuantX Biosciences's product category is Computational Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.